Moazzam Shahzad: Exploring allo-HCT outcomes in geriatric patients
Moazzam Shahzad, Chief Hematology-Oncology Fellow at Moffitt Cancer Center, shared a recent article on X:
“Excited to share our first 2025 publication addressing a critical gap by exploring allo-HCT outcomes in geriatric patients, a historically underrepresented group in clinical trials due to toxicity and mortality concerns.”
Authors: Moazzam Shahzad, Qamar Iqbal, Muhammad Kashif Amin, Amir Kasaiean,Iman Menbari Oskouie, Sarmad Zaman Warraich, James Yu, Iqra Anwar, Michael Jaglal and Muhammad Umair Mushtaq
Moazzam Shahzad, MD, is a Hematology and Medical Oncology Chief Fellow at the H. Lee Moffitt Cancer Center and Research Institute/University of South Florida Morsani College of Medicine in Tampa, FL. His research focuses on the tumor immune microenvironment and advanced cellular therapies, including hematopoietic stem cell transplants and chimeric antigen receptor (CAR) T cell therapies.
For more updates, follow OncoDaily.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023